Sexually Transmitted Diseases

Even after it was confirmed safe, women living with HIV are neglecting to use the drug dolutegravir, potentially subjecting them to worse HIV treatment outcomes.

Rates of sustained viral suppression among people living with HIV were lower than expected, especially among children and adolescents.

After the intervention, more patients were correctly prescribed nPEP and more follow-up visits were recommended.

Pregnant women with sexually transmitted infections (STIs) were more likely to give birth prematurely.

Adding additional screening methods in combination with standard testing would increase diagnostic accuracy for tuberculosis infection among patients living with HIV.

HIV Stakeholders weigh on the future of PrEP.

A study found trans people were not substantively included in many countries’ HIV national strategic plans, despite being disproportionately impacted by HIV/AIDS.

States with policy that permitted adolescents to independently choose to receive HPV vaccination had a significantly higher immunization uptake.

How 1 provider is training medical peers to offer PrEP education and prescribe it.

Bias against injection drug users can inhibit them from receiving potentially lifesaving care, such as HIV pre-exposure prophylaxis (PrEP). Community-based responses like syringe service programs help combat this stigma.

Fenway Health’s Pride in Our Health podcast is an example of new voices being heard, and an alternative means of getting health information to the general public.

Adding genotypic resistance testing (GRT) to routine care did not improve HIV virologic outcomes for patients for whom first-line ART failed, the study authors wrote.

Long-acting cabotegravir plus rilpivirine worked with or without a lead-in for ART-naïve HIV patients.

A new study looks at this population and what factors affect outcomes, including diagnosis. This is significant not only for pandemic response, but also preparedness for vulnerable patient populations.

People who inject drugs (PWID) remain at risk of HIV infection, according to a recent report by the CDC, which found HIV infection and HIV-associated behaviors remained steady between 2015 and 2018.

29% of cisgender men who have sex with men acquired HIV despite being designated as “low risk.”

In Gilead’s BICSTaR trial of their full HIV treatment regimen Biktarvy, 97% of treatment-naïve adults and 96% of treatment-experienced adults achieved virological suppression after 1 year.

The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.

Merck recently announced results looking at their islatravir implant studied for HIV prevention for 3 months. The long-term goal is to have the implant last 12 months following administration.

Children living with HIV have a new once-daily treatment option to maintain virologic suppression.

Comparing 2020 to 2019, investigators saw a reduction in the number of HIV tests, the number of in-person consultations, and new enrollments in care, due to the disruption in HIV care throughout the COVID-19 pandemic.

There are MSM who are indicated for PrEP use that don’t use it, and vice versa, the study authors found.

This promising class of therapy is an expanding treatment option for people who are looking for HIV prevention offerings.

The TakeMeHome program, a public-private partnership to distribute HIV self-test home kits to at-risk populations, is reaching at-risk individuals who weren’t otherwise accessing testing.